Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression

Genes and Development

Volumn 19, Issue 15, 2005, Pages 1779-1786

  Ma, Li ^a,b   Teruya Feldstein, Julie ^a   Behrendt, Nille ^a   Chen, Zhenbang ^a   Noda, Tetsuo ^c   Hino, Okio ^c   Cordon Cardo, Carlos ^a   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c CANCER INSTITUTE   (Japan)

Author keywords

Haploinsufficiency; Prostate cancer; PTEN; TSC2

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUBERIN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ANALYSIS; HAPLOIDY; HETEROZYGOSITY; HETEROZYGOSITY LOSS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; GENOTYPE; HAPLOTYPES; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICE; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 23744484194     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1314405     Document Type: Article

References (31)

1. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J.G., Jen, J., Isaacs, W.B., Bova, G.S., and Sidransky, D. 1997. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57: 4997-5000.
2. Cantley, L.C. and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. 96: 4240-4245.
3. Di Cristofano, A. and Pandolfi, P.P. 2000. The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
4. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19: 348-355.
5. +/- mice. Science 285: 2122-2125.
6. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P.P. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27: 222-224.
7. Gingras, A.C., Raught, B., and Sonenberg, N. 2001. Regulation of translation initiation by FRAP/mTOR. Genes & Dev. 15: 807-826.
8. Gomez, M.R., Sampson, J.R., and Whittemore, V.H. 1999. Tuberous sclerosis complex. Oxford University Press, New York.
9. Gray, I.C., Phillips, S.M., Lee, S.J., Neoptolemos, J.P., Weissenbach, J., and Spurr, N.K. 1995. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 55: 4800-4803.
10. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R., et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166: 213-223.
11. Hay, N. and Sonenberg, N. 2004. Upstream and downstream of mTOR. Genes & Dev. 18: 1926-1945.
12. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657.
13. Inoki, K., Zhu, T., and Guan, K.L. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
14. Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G., and Lamb, R. 2002. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide- 3-OH kinase is mTOR independent. J. Cell Biol. 159: 217-224.
15. Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
16. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59: 1206-1211.
17. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P.P. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
18. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10: 151-162.
19. Manning, B.D., Logsdon, M.N., Lipovsky, A., Abbott, D., Kwiatkowski, D.J., and Cantley, L.C. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes & Dev. (this issue).
20. +/- mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104: 687-695.
21. Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M., Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., and Parsons, R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. 96: 1563-1568.
22. Potter, C.J., Huang, H., and Xu, T. 2001. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105: 357-368.
23. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
24. Shah, O.J., Wang, Z., and Hunter, T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14: 1650-1656.
25. Shao, X., Tandon, R., Samara, G., Kanki, H., Yano, H., Close, L.G., Parsons, R., and Sato, T. 1998. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int. J. Cancer 77: 684-688.
26. Suzuki, A., de la Pompa, J.L., Stambolic, V., Elia, A.J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., et al. 1998a. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8: 1169-1178.
27. Suzuki, H., Freije, D., Nusskern, D.R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W.B., and Bova, G.S. 1998b. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58: 204-209.
28. Suzuki, A., Itami, S., Ohishi, M., Hamada, K., Inoue, T., Komazawa, N., Senoo, H., Sasaki, T., Takeda, J., Manabe, M., et al. 2003. Keratinocyte- specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 63: 674-681.
29. Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E., and Hariharan, I.K. 2001. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105: 345-355.
30. You, M.J., Castrillon, D.H., Bastian, B.C., O'Hagan, R.C., Bosenberg, M.W., Parsons, R., Chin, L., and DePinho, R.A. 2002. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. 99: 1455-1460.
31. Zhang, H., Cicchetti, G., Onda, H., Koon, H.B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C.L., and Kwiatkowski, D.J. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112: 1223-1233.